Bluesky Facebook Reddit Email

Estrogren plus progestin decreases colorectal cancer in postmenopausal woman

03.03.04 | LA BioMed

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

In July 2002, WHI researchers reported a 26% increase in breast cancer for postmenopausal women taking estrogen plus progestin. In June 2003, researchers reported that the combination hormone therapy may also stimulate breast cancer growth and delay breast cancer diagnosis. In this current study, researchers conclude that short-term use of estrogen plus progestin is associated with a decreased incidence of colorectal cancers. However, these cancers are diagnosed at more advanced stage perhaps related to symptom misinterpretation or other reasons requiring further study.

According to Dr. Chlebowski: "The effects of estrogen plus progestin suggest that use of these hormones can delay diagnosis of breast and colorectal cancer, two of the three most common malignancies of postmenopausal women. The risks and benefits of combined hormone use should be evaluated prior to beginning this treatment."

Citation: The New England Journal of Medicine, March 4, 2004

New England Journal of Medicine

Keywords

Article Information

Contact Information

Rowan Chlebowski, MD, PhD
rchlebow@whi.org

How to Cite This Article

APA:
LA BioMed. (2004, March 3). Estrogren plus progestin decreases colorectal cancer in postmenopausal woman. Brightsurf News. https://www.brightsurf.com/news/1EK45651/estrogren-plus-progestin-decreases-colorectal-cancer-in-postmenopausal-woman.html
MLA:
"Estrogren plus progestin decreases colorectal cancer in postmenopausal woman." Brightsurf News, Mar. 3 2004, https://www.brightsurf.com/news/1EK45651/estrogren-plus-progestin-decreases-colorectal-cancer-in-postmenopausal-woman.html.